Stem Cell Therapy
Type 1 diabetes mellitus diabetes (T1DM) is ranked as the 7th leading cause of death in the US. T1DM is an autoimmune disease that causes destruction of the β-cells of the pancreas, which results in insulin deficiency. Mainstay treatments involve short-term glycemic control through injectable insulin. More recently, views have shifted from supportive care treatment of T1DM towards cell replacement therapies. In December 2019, Diomics entered into a Sponsored Research Agreement (SRA) with Dr. Jonathan Lakey and the University of California, Irvine. The SRA is focused on validation of patent claims filed by Diomics in 2019 encompassing the use of DiomatTM as an encapsulating matrix and scaffold for β-cells & stem cells in surgical implants for use in cell-based therapies. The 2019 applications also cover the use of DiomatTM foams and ultra-thin films as transdermal delivery agents for therapeutic & cosmetic applications including delivery of cell therapy products, medicinals & nutraceuticals for wound healing, pain management, dental applications & beauty treatments.
Transdermal Delivery
The DiomatTM polymer can be formulated into 0.05mm hydrophilic ultrathin films which can be loaded with medicinals and bio-absorbed rapidly through the skin, thus bypassing the liver and absorbed directly into the bloodstream. The DiomatTM transdermal polymers serve as a dissolvable loading matrix and delivery vehicle for transdermal cosmeceuticals, nutraceuticals & drug delivery applications. The Sponsored Research Agreement with Dr. Jonathan Lakey and the University of California, Irvine will also include methods development for DiomatTM transdermal delivery of exosomes for treatment of diabetic ulcers, wound healing and for selected beauty treatments.
License Opportunities for DNA Capture & Release
The versatile DiomatTM polymer can also be formulated into dissolvable foams that can used to efficiently recover DNA from biological samples for diagnostics, forensics & biohazard detection applications. DiomatTM can be fashioned to produce swabs, kits and collection devices for efficient and automated recovery of DNA from blood, urine & buccal samples. Unlike cotton or rayon used in most collection systems today, DiomatTM polymer completely dissolves in buffers compatible with DNA extraction reagents; this property eliminates operator handling steps, enables automation, improved reproducibility and significantly increases recovery of DNA from low content biological samples. The DNA captured using DiomatTM polymer collection swabs, kits and devices can be analyzed by PCR, DNA sequencing & other nucleic acid detection methods and has broad applicability for development of applications for DNA diagnostics, forensic sciences & detection of airborne pathogens. Diomics is excited to offer both exclusive and non-exclusive licenses defined by jurisdictional territories and fields of use, for the development of products for applications in humans and animals.